Science Pool

Impact of Pre-incubation Time on Transporter Inhibition Potency

The third webinar in our series on drug transporters was presented by Felix Huth from Novartis.

About the Webinar

For some inhibitor compounds, pre-incubation with the inhibitor leads to more potent IC₅₀ values in uptake transporter inhibition assays. One contributing factor to the higher inhibition potency is the time required to reach steady state concentrations for the inhibitor. The dependent factors influencing this equilibration time will be described as well as the clinical relevance.

About the Speaker

Felix Huth PhD ADME Scientist | Novartis Felix Huth received his PhD in Natural Product Chemistry from the University of Göttingen, Germany. After starting his career in a Biotech company in 1999, he joined the pharmaceutical company Altana in 2004 as biotransformation specialist. He extended his ADME knowledge, i.e. in enzyme and transporter kinetics, PBPK modeling and DDI. After joining Novartis in 2013, he developed in the role of an ADME/DDI specialist with focus on transporters and PBPK modeling, reflected by more than 20 peer-reviewed publications.

Watch the webinar to learn more!

[hs-form id="5385d516-f2dd-4038-8e90-5eb7b3e85574" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Sciencepool/Videos%20and%20Webinars/Cyprotex%20webinars%20and%20videos/focus-on-drug-transporters-webinar-series-felix-huth-novartis-sept2020.m4v"]

P-gp Transport Kinetics - Compound-Specific Selection of In Vitro Assay Design and Kinetic Parameter Estimation

The second webinar in this series on drug transporters was presented by Birk Poller from Novartis.

About the Webinar

Robust and reliable determination of the kinetic parameters for efflux transporters, primarily P-glycoprotein, has remained a challenging task. Different cell types, assay setups and kinetic models together with the physicochemical drug properties affect the outcome of in vitro studies. In this webinar, the results of a systematic study will be presented together with a compound-specific guidance for the assessment of efflux transporter kinetics.

About the Speaker

Birk Poller Senior Principal Scientist | Novartis Birk Poller is an ADME Scientist at Novartis, working in the Pharmacokinetic Sciences department. He is responsible for in vitro permeability and drug transport studies and acts as deputy lead for an in vitro enzyme, transporter and plasma protein binding group. In addition, Birk Poller serves as ADME and DDI expert in cross-functional project teams throughout the translational drug development phases. His recent research on elucidating the interplay between drug transport and metabolism in the context of clearance prediction and drug-drug interactions resulted in several scientific publication. Before joining Novartis in 2010, Birk obtained his PhD from the University of Basel, Switzerland and he conducted postdoctoral research in blood-brain barrier pharmacokinetics at the Netherland Cancer Institute in Amsterdam.

Watch the webinar to learn more!

[hs-form id="abfbeada-8b42-41c2-b2a4-80a3e39c771e" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Sciencepool/Videos%20and%20Webinars/Cyprotex%20webinars%20and%20videos/focus-on-drug-transporters-webinar-series-birk-poller-novartis-sept2020.m4v"]

Quantitative Prediction of Drug-Drug Interactions with Common Statin Co-meds: A Framework for Decision-making within Drug Discovery/Development

The first webinar in this series on drug transporters was presented by Hayley Atkinson from Cyprotex.

About the Webinar

Due to polypharmacy, drug-drug interactions (DDIs) continue to account for 5% of UK hospital admissions and as such remain a major regulatory concern. This is particularly true for common co-meds such as statins which due to their prescribing prevalence in patients with co-morbidities have high potential for DDI. Within Drug Discovery and Development we are moving away from relatively simple hazard identification of DDI potential using basic static equations detailed in regulatory guidance to actual risk analysis and mitigation using quantitative prediction of DDI. Using mechanistic static equations we can predict the AUC change of each statin due to inhibition of its critical enzyme/transporter pathway(s) so that the clinical team can make a decision on whether any potential DDI is simply a pharmacokinetic DDI or a clinically significant DDI requiring intervention. The statin mechanistic equation model requires very few in vitro input parameters and can be utilised towards aiding preclinical development candidate selection and towards reducing unexpected clinical findings in patients providing a useful tool in Drug Discovery and Early Development.

About the Speaker

Hayley Atkinson PhD Associate Principal Scientist | Cyprotex Hayley Atkinson is an Associate Principal Scientist in the permeability and drug transporter team at Cyprotex, UK where she acts as deputy scientific lead for drug transporter studies.  Her research interests include prediction of transporter mediated drug-drug interactions with improved in vitro assays.  Prior to joining Cyprotex in 2013, Hayley received her PhD from the University of Liverpool under Prof. Munir Pirmohamed where she conducted research on anti-epileptic drug transporters at the blood-brain barrier in the context of drug resistance.

Watch the webinar to learn more!

[hs-form id="e52f470e-0e88-41ac-99f1-349b2316ef8a" show="hide on login" url="https://news.evotecsciencepool.com/hubfs/Sciencepool/Videos%20and%20Webinars/Cyprotex%20webinars%20and%20videos/focus-on-drug-transporters-webinar-series-hayley-atkinson-cyprotex-sept2020.m4v"]

Don't miss our educational webinar. In-house expert, Ellenia Bordini, will cover various early stage "alternative approaches" for the evaluation of metabolites in human and preclinical species, and how these can be used to direct preclinical safety testing for regulatory submission. 

Fireside Chat at BIO-Europe 2021

Evotec Chief Scientific Officer, Dr Cord Dohrmann, talks to Dr Hubert Birner, Managing Partner at TVM Capital Life Sciences, about how Evotec has built an impressive and innovative platform.

WATCH NOW